serum/glucocorticoid regulated kinase family member 3Genealiases: CISK · SGK2 · SGKL
Q-omics provides the consensus-scored SGK3 profile across patient tissues and cancer cell-line models. SGK3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SGK3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SGK3 RNA expression shows 20,209 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where SGK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SGK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SGK3 survival associations across molecular data types. SGK3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SGK3 RNA expression–survival associations across cancer types. High SGK3 expression shows unfavorable associations in UVM, but favorable associations in KIRC, BRCA, SKCM, HNSC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SGK3 RNA expression.
This table summarizes SGK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SGK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SGK3 shows lower tumor expression in LUAD and higher tumor expression in KIRC, THCA, HNSC, LIHC and STAD. The KIRC box plot shows higher SGK3 RNA expression in tumor versus normal tissue (log2 FC = +0.473, t-test p < 0.001).
This table shows molecular features associated with SGK3 in patient tissues and cancer cell lines. In patient samples, SGK3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SGK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
